Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing

被引:48
作者
Ando, Y
Minami, H
Saka, H
Ando, M
Sakai, S
Shimokata, K
机构
[1] NAGOYA UNIV, SCH MED, DEPT INTERNAL MED 1, SHOWA KU, NAGOYA, AICHI 466, JAPAN
[2] SHINSHIRO MUNICIPAL HOSP, DEPT INTERNAL MED, SHINSHIRO, AICHI 44113, JAPAN
[3] NATL CANC CTR HOSP E, DEPT HEMATOL ONCOL, KASHIWA, CHIBA 277, JAPAN
[4] JAPANESE RED CROSS NAGOYA FIRST HOSP, DEPT INTERNAL MED, NAKAMURA KU, NAGOYA, AICHI 453, JAPAN
[5] NAGOYA UNIV, SCH MED, CLIN PREVENT SERV, SHOWA KU, NAGOYA, AICHI 466, JAPAN
关键词
carboplatin; pharmacokinetics; chemotherapy; glomerular filtration rate; creatinine clearance;
D O I
10.1038/bjc.1997.509
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Carboplatin clearance depends on the glomerular filtration rate (GFR), and Calvert's formula is frequently used to achieve a target area under the time vs concentration curve (mg ml(-1) min). Creatinine clearance is a substitute for GFR when creatinine Values are determined by the Jaffe method, which is being replaced by the enzymatic method. When the enzymatic method is used, the corresponding creatinine clearance theoretically exceeds GFR, and the use of creatinine clearance as GFR in Calvert's formula results, accordingly, in overdosing of carboplatin. In this study, we have established a model for adjusting the creatinine clearance to offset this bias based on a relationship between creatinine values measured by the Jaffe method and by the enzymatic method: adjusted creatinine clearance (ml min(-1)) = creatinine clearance (mi min(-1)) x [serum creatinine (mg dl(-1))]/[serum creatinine (mg dl(-1)) + 0.2]. Subsequently, we Validated this model using the data from 35 lung cancer patients. Estimated clearances of carboplatin with the original equation [creatinine clearance + 25] were systematically higher than observed clearances [mean prediction error (MPE) +/- standard error (s.e.) = 26 +/- 5%]. This positive bias was corrected by the adjustment (MPE +/- s.e. = 5 +/- 4%). When the enzymatic method is used, the adjusted creatinine clearance should be used in Calvert's formula.
引用
收藏
页码:1067 / 1071
页数:5
相关论文
共 24 条
  • [1] Pharmacokinetic study of carboplatin given on a 5-day intravenous schedule
    Ando, Y
    Minami, H
    Saka, H
    Ando, M
    Sugiura, S
    Sakai, S
    Shimokata, K
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 1997, 88 (05): : 517 - 521
  • [2] CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION
    CALVERT, AH
    NEWELL, DR
    GUMBRELL, LA
    OREILLY, S
    BURNELL, M
    BOXALL, FE
    SIDDIK, ZH
    JUDSON, IR
    GORE, ME
    WILTSHAW, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) : 1748 - 1756
  • [3] PREDICTION OF CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL PATIENT CHARACTERISTICS
    CHATELUT, E
    CANAL, P
    BRUNNER, V
    CHEVREAU, C
    PUJOL, A
    BONEU, A
    ROCHE, H
    HOUIN, G
    BUGAT, R
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (08): : 573 - 580
  • [4] Prediction of carboplatin clearance from standard morphological and biological patient characteristics - Response
    Chatelut, E
    Chevreau, C
    Canal, P
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (03) : 261 - 262
  • [5] EVALUATION OF AN ENZYMATIC METHOD FOR DETERMINING CREATININE IN PLASMA
    CROCKER, H
    SHEPHARD, MDS
    WHITE, GH
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1988, 41 (05) : 576 - 581
  • [6] DAUGAARD G, 1988, CANCER CHEMOTH PHARM, V21, P163
  • [7] A CLINICAL APPRAISAL OF PLASMA CONCENTRATION AND ENDOGENOUS CLEARANCE OF CREATININE
    DOOLAN, PD
    ALPEN, EL
    THEIL, GB
    [J]. AMERICAN JOURNAL OF MEDICINE, 1962, 32 (01) : 65 - &
  • [8] FABINY DL, 1971, CLIN CHEM, V17, P696
  • [9] DOSE INTENSITY OF CARBOPLATIN IN COMBINATION WITH CYCLOPHOSPHAMIDE OR IFOSFAMIDE
    GREEN, JA
    SMITH, K
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 26 : S22 - S25
  • [10] GUDER WG, 1986, J CLIN CHEM CLIN BIO, V24, P889